NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 3, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

NPC

Interventions

DRUG

Pembrolizumab

200mg every 3 weeks infusion

Trial Locations (2)

Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong

National Cancer Centre of Singapore, Singapore

All Listed Sponsors

lead

Chinese University of Hong Kong

OTHER

NCT03734809 - NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer | Biotech Hunter | Biotech Hunter